Headline Stocks to Watch in July 2024: BSFC, KAVL, VTAK, PRSO, INBS

Getting your Trinity Audio player ready...

Blue Star Foods Corp (NASDAQ: BSFC): An international seafood company specializing in refrigerated pasteurized crab meat and other premium seafood products. The stock surged over 100%, trading above $3.50 per share, driven by a forecast of at least 65% revenue growth in 2024 and an annual run-rate exceeding $20 million. The company’s positive outlook is attributed to product line expansion, increased market penetration, and strengthened distribution channels.

Kaival Brands Innovations Group Inc. (NASDAQ: KAVL): The exclusive U.S. distributor of BIDI® Stick and global distributor of VEEBA® through Philip Morris Products SA (NYSE: PM), raised approximately $6 million through a public offering on June 24. The stock is up 26.44% since June 21, 2024. The proceeds will support working capital, corporate purposes, operations, and business expansion.

Catheter Precision Inc. (NYSE American: VTAK): Gained attention after announcing its first purchase order from Qatar following an evaluation of its VIVO product. Trading volumes have surged, positioning the stock in breakout territory, up 25.2% in June 2024. The VIVO system aids in identifying ventricular arrhythmias before procedures, while the LockeT closure retention device enhances patient care.

Peraso Inc. (NASDAQ: PRSO): Introduced a new wireless platform for secure tactical communications using 60 GHz mmWave technology, featured in “MicrowaveJournal.” The platform supports low-latency, high-bandwidth applications, opening opportunities in the defense sector. Fiscal Q1 2024 results showed net revenue of $2.8 million, up from $1.8 million the previous quarter. The technology is integrated into Panasonic Corporation’s (Tokyo: 6752.T) (OTC: PCRFF) systems across Japan.

Intelligent Bio Solutions Inc. (NASDAQ: INBS): Signed two major UK warehouse and logistics customers, implementing Intelligent Fingerprinting Drug Screening. The company began dosing for its FDA-supporting pharmacokinetic study, expecting results by the end of July, following a shift to a global operations framework.